Illumina, Inc. (ILMN) Shares Bought by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,544,831 shares of the life sciences company’s stock after purchasing an additional 44,816 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Illumina were worth $337,530,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of ILMN. Financial Gravity Companies Inc. acquired a new stake in shares of Illumina during the 4th quarter valued at $106,000. Dupont Capital Management Corp acquired a new stake in shares of Illumina during the 3rd quarter valued at $153,000. SeaCrest Wealth Management LLC acquired a new stake in shares of Illumina during the 4th quarter valued at $154,000. Captrust Financial Advisors acquired a new stake in shares of Illumina during the 4th quarter valued at $165,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in shares of Illumina by 113.9% during the 4th quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock valued at $168,000 after acquiring an additional 410 shares in the last quarter. 91.51% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Robert S. Epstein sold 250 shares of Illumina stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $231.25, for a total value of $57,812.50. Following the completion of the transaction, the director now directly owns 7,088 shares of the company’s stock, valued at approximately $1,639,100. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $224.50, for a total value of $32,552.50. Following the completion of the transaction, the senior vice president now directly owns 7,411 shares of the company’s stock, valued at $1,663,769.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,887 shares of company stock valued at $16,510,025. Corporate insiders own 0.89% of the company’s stock.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The business had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. During the same period last year, the company earned $0.85 EPS. Illumina’s revenue for the quarter was up 25.7% compared to the same quarter last year. equities research analysts anticipate that Illumina, Inc. will post 4.59 earnings per share for the current year.
ILMN has been the topic of several recent research reports. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Barclays raised their price objective on Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a report on Wednesday, January 31st. Cowen raised their price objective on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, January 22nd. Morgan Stanley raised their price objective on Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a report on Wednesday, January 31st. Finally, BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $241.39.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.